Collaboration and Licensing Agreements (Tables)

6 Months Ended

Jun. 30, 2020

Collaboration and Licensing Agreements

Schedule of revenue by licensees

The revenues recorded for the three and six months ended June 30, 2020 were earned principally from the following licensees (in millions):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
Aimmune	$	—	$	—	$	9.6	$	—
Alexion		3.8		5.1		7.2		5.1
Astellas		0.7		13.8		0.9		13.8
Genentech		0.8		0.6		1.5		112.5
Gilead		7.5		—		13.5		—
MorphoSys		—		—		12.5		—
Vir Biotechnology		0.3		—		0.3		—
Total	$	13.1	$	19.5	$	45.5	$	131.4

Schedule of disaggregation of revenue

The table below summarizes the disaggregation of revenue recorded for the three and six months ended June 30, 2020 (in millions):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
Research collaboration	$	1.5	$	14.4	$	2.4	$	14.7
Milestone		0.3		4.0		12.8		4.0
Licensing		7.5		—		23.1		111.6
Royalties		3.8		1.1		7.2		1.1
Total	$	13.1	$	19.5	$	45.5	$	131.4